Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 12/2011

01-12-2011 | Review Article

Methotrexate for rheumatoid arthritis patients who are on hemodialysis

Authors: Hasanein Al-Hasani, Euthalia Roussou

Published in: Rheumatology International | Issue 12/2011

Login to get access

Abstract

Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.
Literature
1.
Owen WF, Lew NL, Liu Y, Lowrie EG (1993) The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001–1006PubMedCrossRef
2.
Cheung KK, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK (2009) Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol 15(4):177–180PubMedCrossRef
3.
Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21(7):1395–1403
4.
Rosen G, Caparros B, Huros AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma. Cancer 49:1221–1230PubMedCrossRef
5.
Thierry FX, Vernier I, Dueymes JM, Roche H, Canal P, Meens F, Pourrat JP, Conte JJ (1989) Acute renal failure after high dose MTX therapy. Nephron 51:416–417PubMedCrossRef
6.
Hande KR, Balow JE, Drake JC (1977) Methotrexate and haemodalyisis. Ann Intern Med 87:495–496PubMed
7.
Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2006) Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. Am J Med Sci 332(3):156–158PubMedCrossRef
8.
Stoller RG, Kenneth RH, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 297:630–634
9.
Feagan BG, Rochon J et al (1995) Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigations. N Engl J Med 332:292–297PubMedCrossRef
10.
Basile C, Montanaro A, Semeraro A (2002) Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transpl 17(3):530–531
11.
Chess JA, Scholey G, Mikhail AI (2004) Neutropenia associated with the use of low-dose methotrexate in a peritoneal dialysis patient. Nephrol Dial Transpl 19(8):2158–2159
12.
Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272–276PubMedCrossRef
13.
Ellman MH, Ginsberg D (1990) Low dose methotrexate and severe neutropaenia in patients undergoing renal dialysis. Arthritis Rheum 33:1060–1061PubMedCrossRef
14.
Clatham WW, Morgan SL, Alarcon GS (2000) Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum 43:1185–1186CrossRef
15.
Chester KA, Baker M, Mayer A (2005) Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol 1(4):549–559
16.
Hammoudeh M (2006) Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford) 45:357–359CrossRef
17.
Gottenberg JE, Merle-Vincent F, Bentaberry F, Alanore Y, Berenbaum F, Fautrel B, Combe B, Durbarch A, Sibilia J, Dougados M, Mariette X (2003) Anti tumour necrosis factor a therapy in 15 patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 48:2019–2024PubMedCrossRef
18.
Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinouria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573PubMedCrossRef
19.
Hueber AJ, Tunc A, Schett G, Manger B (2007) Anti-tumour necrosis alpha therapy in patients with impaired renal function Ann. Rheum Dis 66:981–982CrossRef
20.
Nestorov I (2005) Clinical pharmacokinetics of tumour necrosis factor antagonists. J Rheumatol 32(74):13–18
21.
Singh R, Cuchacovich R, Huang W, Espinoza LR. (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol 29 (3):636–637
Metadata
Title
Methotrexate for rheumatoid arthritis patients who are on hemodialysis
Authors
Hasanein Al-Hasani
Euthalia Roussou
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2041-5

Other articles of this Issue 12/2011

Rheumatology International 12/2011 Go to the issue

Original Article

Evaluation of osteoarthritis induced by treadmill-running exercise using the modified Mankin and the new OARSI assessment system

Original Article

Circulating endothelial microparticles in children with Henoch–Schönlein purpura; preliminary results

Original Article

Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients

Short Communication

Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature

Letter to the Editor

Immunoglobulins during different treatment regimes in Schnitzler’s syndrome

Original Article

The impact factor of rheumatology journals: an analysis of 2008 and the recent 10 years
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits